Suppr超能文献

急性感染性胃肠炎中合生元的成本效益:花钱来省钱。

Cost/benefit of synbiotics in acute infectious gastroenteritis: spend to save.

机构信息

Department of Pediatrics, Universitair KinderZiekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium.

出版信息

Benef Microbes. 2012 Sep;3(3):189-94. doi: 10.3920/BM2012.0007.

Abstract

The cost/benefit ratio of probiotics in the ambulatory treatment of acute infectious gastro-enteritis with or without a synbiotic food supplement (containing fructo-oligosaccharides and probiotic strains of Streptoccoccus thermophilus, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium lactis and Bifidobacterium infantis) has been studied. 111 children (median age 37 and 43 months for the synbiotic and placebo group, respectively) with acute infectious gastroenteritis were included in a randomised, prospective placebo-controlled trial performed in primary health care. All children were treated with an oral rehydration solution and with the synbiotic food supplement (n=57) or placebo (n=54). Physicians were allowed to prescribe additional medication according to what they considered as 'necessary'. Cost of add-on medication and total healthcare cost were calculated. Median duration of diarrhoea was 1 day shorter (95% confidence interval -0.6 to -1.9 days) in the symbiotic than in the placebo group (P<0.005). Significantly more concomitant medication (antibiotics, antipyretics, antiemetics) was prescribed in the placebo group (39 prescriptions in 28 patients) compared to the synbiotic group (12 prescriptions in 7 patients) (P<0.001). The difference was most striking for antiemetics: 28 vs. 5 prescriptions. The cost of add-on medication in the placebo group was evaluated at € 4.04/patient (median 4.97 (interquartile (IQ) 25-75: 0-4.97)) vs. € 1.13 /patient in the synbiotic arm (P<0.001). If the cost of the synbiotic is considered, median cost raised to € 7.15/patient (IQ 25-75: 7.15-7.15) (P<0.001). The extra consultations needed to prescribe the concomitant medication resulted in a higher health care cost in the placebo group (€ 14.41 vs. € 10.74/patient, P<0.001). Synbiotic food supplementation resulted in a 24 h earlier normalisation of stool consistency. Although use of the synbiotic supplementation increased cost, add-on medication and extra consultations were reduced, resulting in a reduction of health care cost of 25%.

摘要

研究了益生菌在伴有或不伴有合生素(含有低聚果糖和嗜热链球菌、鼠李糖乳杆菌、嗜酸乳杆菌、双歧杆菌 lactis 和双歧杆菌 infantis 的益生菌菌株)的急性传染性胃肠炎的门诊治疗中的成本/效益比。111 名儿童(中位数年龄分别为合生素组 37 个月和安慰剂组 43 个月)患有急性传染性胃肠炎,在初级保健中进行了一项随机、前瞻性安慰剂对照试验。所有儿童均接受口服补液治疗和合生素食品补充剂(n=57)或安慰剂(n=54)治疗。医生可以根据他们认为“必要”的情况开具额外的药物。计算了附加药物的费用和总医疗费用。与安慰剂组相比,合生素组的腹泻持续时间缩短了 1 天(95%置信区间 -0.6 至 -1.9 天)(P<0.005)。在安慰剂组中开具了更多的伴随药物(抗生素、退烧药、止吐药)(28 名患者中 39 份处方),而在合生素组中(7 名患者中 12 份处方)(P<0.001)。止吐药的差异最为明显:28 比 5 份处方。安慰剂组附加药物的费用评估为 4.04 欧元/患者(中位数 4.97(四分位距 (IQR) 25-75:0-4.97)),而合生素组为 1.13 欧元/患者(P<0.001)。如果考虑合生素的成本,中位数成本增加到 7.15 欧元/患者(IQR 25-75:7.15-7.15)(P<0.001)。为开具伴随药物而额外进行的咨询导致安慰剂组的医疗保健费用更高(€ 14.41 比 € 10.74/患者,P<0.001)。合生素食品补充剂使粪便稠度在 24 小时内更早恢复正常。尽管使用合生素补充剂增加了成本,但附加药物和额外咨询减少了,从而使医疗保健成本降低了 25%。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验